The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...

Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly and Novo Nordisk are competing for ...

By Rishika Sadam HYDERABAD (Reuters) -Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its price ...

"Obesity is a complex, chronic condition that requires more than just treatment--it demands continuous medical education, empathy, and coordinated action across the healthcare ecosystem," said Dr.

Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs. The company is set to capture 50% of the $95 billion obesity market by 2050.

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.